Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Showing results for "1"

Research

Dahlem Conference

There is increasing evidence that the functional state of the immune system at birth is predictive of the kinetics of immune maturation in early infancy.

Research

Toll-like receptor 7 function is reduced in adolescents with asthma

Anti-viral innate immune responses may be impaired in asthma, although the mechanisms are not well understood.

Research Assistant - Leukaemia Research

We are a collaborative group focused on improving outcomes for children with leukaemia. The Research Assistant will evaluate novel therapeutics in

Research Nurse / Clinical Study Co-ordinator - Northern Territory

Patient recruitment, sample collection & coordination of a clinical study in patients with rheumatic heart disease.

PhD scholarship

PhD Scholarship opportunities The Rio Tinto Children’s Diabetes Centre; A JDRF Global Centre of Excellence, (“the Centre”) based at The Kids Research

News & Events

CoDiab study

Kayla Hesketh is the first patient recruited to a new study being carried out by the Children’s Diabetes Centre and University Children’s Hospital Basel.

RESP-ACT

The aim of RESP-ACT is to reduce these children’s respiratory hospital admissions and visits to Emergency Department, and to help them and their families to have as the best possible quality of life.

Research

“If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trials

Each year, approximately 1000 children in Australia and New Zealand, aged 0–14 years, are diagnosed with cancer. Despite paediatric cancer accounting for less than 1% of all cancer cases, the impact on their families and communities is profound and disproportionate.

Research

Acute Lymphoblastic Leukemia in Infants: A Distinctive, High-Risk Subtype of Childhood Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) in infants younger than 1 year of age is an aggressive, high-risk subtype of childhood ALL. Infant ALL with KMT2A-r is characteristically poorly responsive to chemotherapy and hematopoietic stem cell transplantation. New strategies, such as molecularly targeted therapies and immunotherapies, are in development and show promise in preclinical models and early phase studies.

Research

Interferon β-1a ring prophylaxis to reduce household transmission of SARS-CoV-2: a cluster randomised clinical trial

Accumulating evidence indicates that an early, robust type 1 interferon (IFN) response to SARS-CoV-2 is important in determining COVID-19 outcomes, with an inadequate IFN response associated with disease severity. Our objective was to examine the prophylactic potential of IFN administration to limit viral transmission.